Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The beta-adrenoceptor

M Johnson1

  • 1Respiratory Therapeutic Development, Glaxo Wellcome Research and Development, Uxbridge, Middlesex, United Kingdom.

American Journal of Respiratory and Critical Care Medicine
|November 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study.

The American journal of psychiatry·1995
Same author

Assessment of hibernating myocardium by dobutamine stimulation in a canine model.

Journal of the American College of Cardiology·1995
Same author

Essential thrombocytosis: underemphasized cause of large-vessel thrombosis.

Journal of vascular surgery·1995
Same author

Healing determinants in older people with leg ulcers.

Research in nursing & health·1995
Same author

Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection.

Cancer letters·1995
Same author

Osteogenic protein-1 induces dendritic growth in rat sympathetic neurons.

Neuron·1995
Same journal

Opportunities for Human Lung Tissue-Based Studies in Fibrotic ILD Research.

American journal of respiratory and critical care medicine·2026
Same journal

Astegolimab in COPD: success or failure?

American journal of respiratory and critical care medicine·2026
Same journal

How artificial intelligence could improve the diagnosis and management of COPD: a perspective from GOLD.

American journal of respiratory and critical care medicine·2026
Same journal

Awake ECMO for ARDS: No Vent, No VILI, No Problem?

American journal of respiratory and critical care medicine·2026
Same journal

Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit during Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial.

American journal of respiratory and critical care medicine·2026
Same journal

Noninvasive Respiratory Support for Adult Patients with Acute Respiratory Failure. An Official American Thoracic Society Clinical Practice Guideline.

American journal of respiratory and critical care medicine·2026
See all related articles

The beta2-adrenoceptor in airway smooth muscle mediates bronchodilation. Receptor desensitization and genetic variations influence asthma severity and response to beta2-agonist therapy.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Genetics

Background:

  • The beta2-adrenoceptor, a Gs protein-coupled receptor, is crucial for bronchodilation in airway smooth muscle.
  • Activation leads to cyclic AMP production, causing airway relaxation via various signaling pathways.

Purpose of the Study:

  • To elucidate the molecular mechanisms of beta2-adrenoceptor activation, desensitization, and the impact of genetic polymorphisms on asthma.
  • To understand how different beta2-agonist properties affect airway smooth muscle response.

Main Methods:

  • Site-directed mutagenesis identified key residues (Asp 113, Ser 204/207) in the beta2-receptor's active site.
  • Characterization of beta2-agonists based on their interaction with the receptor (direct activation, membrane depot, auxiliary site).

Related Experiment Videos

  • Investigation of desensitization pathways involving beta-ARK, beta-arrestin, and receptor recycling.

    • Main Results:

    • Specific mutations confirm the active site critical for agonist binding and activity.
    • Differences in agonist mechanisms (e.g., albuterol, formoterol, salmeterol) correlate with bronchodilation kinetics.
    • Beta-adrenoceptor desensitization involves phosphorylation, uncoupling, internalization, and downregulation, with varying degrees based on cell type and polymorphisms.
    • Polymorphisms (Arg-Gly 16, Glu-Gln 27, Thr-Ile 164) affect receptor behavior and asthma phenotypes.

    Conclusions:

    • Beta2-agonist efficacy is influenced by receptor binding kinetics and desensitization processes.
    • Genetic variations in the beta2-receptor significantly impact asthma severity and treatment response.
    • Further population studies are needed to fully understand the clinical implications of beta2-receptor polymorphisms in asthma.